Complete the submission for tirzepatide in obesity
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 1 Nov 2022
- Due
- 30 Apr 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“complete the submission shortly after SURMOUNT-2 data is available, which is expected in April 2023”
What we found
Evidence strength A What the grades mean
The company confirmed the completed submission of tirzepatide for chronic weight management to the FDA in an August 2023 filing, indicating the commitment was met.
-
A ELI Lilly & Co 8-K filed 2023-08-08
“The completed submission of tirzepatide in chronic weight management to the FDA” ✓ confirmed on the page
Market reaction: the shares moved +15.9% against the S&P 500 over the three sessions around the disclosure (7 Aug 2023 to 10 Aug 2023). What this measures
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Submission for tirzepatide in obesity
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Conditional
- Yes: SURMOUNT-2 data is available
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you ELI Lilly & Co? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-LLY-004538 · Corrections policy